Cargando…
Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy
Although there is only symptomatic treatment for Fukuyama congenital muscular dystrophy (FCMD), several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have been conducted. This study aimed to evaluate the efficacy of steroid ther...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688455/ https://www.ncbi.nlm.nih.gov/pubmed/34930981 http://dx.doi.org/10.1038/s41598-021-03781-z |
_version_ | 1784618354765463552 |
---|---|
author | Murakami, Terumi Sato, Takatoshi Adachi, Michiru Ishiguro, Kumiko Shichiji, Minobu Tachimori, Hisateru Nagata, Satoru Ishigaki, Keiko |
author_facet | Murakami, Terumi Sato, Takatoshi Adachi, Michiru Ishiguro, Kumiko Shichiji, Minobu Tachimori, Hisateru Nagata, Satoru Ishigaki, Keiko |
author_sort | Murakami, Terumi |
collection | PubMed |
description | Although there is only symptomatic treatment for Fukuyama congenital muscular dystrophy (FCMD), several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have been conducted. This study aimed to evaluate the efficacy of steroid therapy for restoring motor functions in FCMD patients. This study involved 3-to-10-year-old FCMD patients who exhibited a decline in motor functions, requested steroid therapy. Patients with consent started oral administration of 0.5-mg/kg prednisolone every alternate day, which was increased to 1.0 mg/kg if the response was inadequate. We used the Gross Motor Function Measure (GMFM) to evaluate and compare the motor functions of all patients. Wilcoxon signed-rank test (significance level, P ≤ 0.05) was used for statistical analysis. At the onset of steroid therapy, 8.10 years (SD, 2.14 years) was the mean age of FCMD patients. The mean GMFM difference between before and after the steroid therapy was + 1.23 (SD, 1.10), and a P value of 0.015 represented significant improvement in GMFM. Our results indicate that steroid therapy may contribute to the maintenance and improvement of the motor functions of advanced-stage FCMD patients. Clinical Trial Registration Registration Number: UMIN000020715, Registration Date: Feb 1st, 2016 (01/02/2016). |
format | Online Article Text |
id | pubmed-8688455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86884552021-12-22 Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy Murakami, Terumi Sato, Takatoshi Adachi, Michiru Ishiguro, Kumiko Shichiji, Minobu Tachimori, Hisateru Nagata, Satoru Ishigaki, Keiko Sci Rep Article Although there is only symptomatic treatment for Fukuyama congenital muscular dystrophy (FCMD), several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have been conducted. This study aimed to evaluate the efficacy of steroid therapy for restoring motor functions in FCMD patients. This study involved 3-to-10-year-old FCMD patients who exhibited a decline in motor functions, requested steroid therapy. Patients with consent started oral administration of 0.5-mg/kg prednisolone every alternate day, which was increased to 1.0 mg/kg if the response was inadequate. We used the Gross Motor Function Measure (GMFM) to evaluate and compare the motor functions of all patients. Wilcoxon signed-rank test (significance level, P ≤ 0.05) was used for statistical analysis. At the onset of steroid therapy, 8.10 years (SD, 2.14 years) was the mean age of FCMD patients. The mean GMFM difference between before and after the steroid therapy was + 1.23 (SD, 1.10), and a P value of 0.015 represented significant improvement in GMFM. Our results indicate that steroid therapy may contribute to the maintenance and improvement of the motor functions of advanced-stage FCMD patients. Clinical Trial Registration Registration Number: UMIN000020715, Registration Date: Feb 1st, 2016 (01/02/2016). Nature Publishing Group UK 2021-12-20 /pmc/articles/PMC8688455/ /pubmed/34930981 http://dx.doi.org/10.1038/s41598-021-03781-z Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Murakami, Terumi Sato, Takatoshi Adachi, Michiru Ishiguro, Kumiko Shichiji, Minobu Tachimori, Hisateru Nagata, Satoru Ishigaki, Keiko Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title | Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title_full | Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title_fullStr | Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title_full_unstemmed | Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title_short | Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy |
title_sort | efficacy of steroid therapy for fukuyama congenital muscular dystrophy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688455/ https://www.ncbi.nlm.nih.gov/pubmed/34930981 http://dx.doi.org/10.1038/s41598-021-03781-z |
work_keys_str_mv | AT murakamiterumi efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT satotakatoshi efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT adachimichiru efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT ishigurokumiko efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT shichijiminobu efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT tachimorihisateru efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT nagatasatoru efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy AT ishigakikeiko efficacyofsteroidtherapyforfukuyamacongenitalmusculardystrophy |